Eisai CoESALF 74 ROE % is -1.44% as of Mar. 2026. GuruFocus rates ESALF with a GF Score™ of 74/100 and a GF Value™ of $36.60 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 936 Drug Manufacturers companies, Eisai Co ranks worse than 55.24% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Eisai Co's annualized net income for the quarter that ended in Mar. 2026 was $-82 Mil. Eisai Co's average Total Stockholders Equity over the quarter that ended in Mar. 2026 was $5,686 Mil. Therefore, Eisai Co's annualized ROE % for the quarter that ended in Mar. 2026 was -1.44%.
The historical rank and industry rank for Eisai Co's ROE % or its related term are showing as below:
ESALF'
s ROE % Range Over the Past 10 Years
Min: 4.43 Med: 6.71 Max: 18.64
Current: 4.47
During the past 13 years, Eisai Co's highest ROE % was 18.64%. The lowest was 4.43%. And the median was 6.71%.
ESALF's ROE % is ranked worse than 55.24% of 936
companies
in the Drug Manufacturers industry
Industry Median: 5.865
vs ESALF: 4.47
Eisai Co (OTCPK:ESALF) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Eisai Co ROE % Related Terms
Eisai Co ROE % Historical Data
* Premium members only.
The historical data trend for Eisai Co's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Eisai Co's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eisai Co ROE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Eisai Co's ROE % distribution charts can be found below:
* The bar in red indicates where Eisai Co's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Eisai Co (ESALF) has a ROE % of -1.44% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Eisai Co and its competitors. Over the past decade, Eisai Co's ROE % has ranged from 4.43 to 18.64. According to the industry distribution chart, Eisai Co ranks #517 out of 936 companies in the Drug Manufacturers industry, placing it in the top 55.2%.
Is Eisai Co's ROE % too high?
Eisai Co's current ROE % is -1.44%. Over the past 10 years, this metric has ranged from a low of 4.43 to a high of 18.64. Based on the distribution chart, Eisai Co ranks #517 out of 936 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Eisai Co has a GF Score™ of 74/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eisai Co's ROE % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Eisai Co ranks #517 out of 936 companies for ROE %. This places Eisai Co in the lower half of its industry. The industry median ROE % is 5.87. Historically, Eisai Co's own ROE % has ranged from 4.43 to 18.64 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Drug Manufacturers company?
The median ROE % among Drug Manufacturers companies is 5.87, based on 936 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Eisai Co and its competitors. For the Drug Manufacturers industry, the median ROE % is 5.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eisai Co's current ROE % is -1.44%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eisai Co stock overvalued right now?
Based on GuruFocus' analysis, Eisai Co (ESALF) is currently considered Significantly Undervalued. The stock's GF Value™ is $36.60, compared to a current price of $25.00 — trading 31.7% below its estimated fair value. The current ROE % is -1.44%. Eisai Co's overall GF Score™ is 74/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Eisai Co (ESALF), the current ROE % is -1.44% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eisai Co (ESALF) Overvalued in 2026?
Based on GuruFocus' analysis, Eisai Co stock appears to be undervalued.
The current stock price of $25.00 is trading 31.7% below its estimated GF Value™ of $36.60.
GuruFocus considers Eisai Co to be Significantly Undervalued.
Key valuation signals for ESALF:
ROE %: -1.44%
GF Value™: $36.60 vs. price of $25.00 (31.7% below fair value)
No single metric tells the full story. See the ESALF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eisai Co Ltd is a specialty and generic drug manufacturing company. The company's business consists of research and development, manufacturing, sales, import, and export of pharmaceuticals. The pharmaceutical business is categorized by region, including East Asia & Global South; Europe, Middle East, Africa, Russia, Oceania (EMEA); Americas; China; and Japan. The company also reports a consumer healthcare business for Japan. The vast majority of the company's revenue is derived from its American pharmaceutical business, followed by its Japanese pharmaceuticals segment. The company utilizes licensing strategies in order to expand its research, development, manufacturing, and marketing capabilities.
74GF Score
Get the complete analysis for ESALF
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ESALF has been successfully added to your 
